• BioCryst disclosed new clinical data for ORLADEYO, with posters scheduled for presentation at the EAACI meeting in Istanbul on June 12-15.
• A long-term pediatric study showed sustained reductions in hereditary angioedema attacks needing rescue medication or professional care, with no new safety signals.
• A post hoc analysis of the early-stage ALPHA-STAR trial found investigational navenibart cut attack burden across patient subgroups, supporting its ongoing Phase 3 program.
• Separate real-world analyses set for EAACI pointed to fewer attacks, lower healthcare use, and strong patient satisfaction for ORLADEYO, including patients switching from other prophylaxis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120700PRIMZONEFULLFEED9745972) on June 12, 2026, and is solely responsible for the information contained therein.